Point-of-Care Drug Reconstitution Devices to 2020


point-of-care drug reconstitution devices   Published June 2014  •  Catalog no. DRS909K  •  Price US $3,850


Growth in the number of injectable drugs supplied in solid form for reconstitution prior to administration is being driven by the increase in drugs based on biological NCEs. These drugs are typically unstable at ambient temperatures and to preserve their shelf life must be either stored at low temperature (the so-call ‘cold chain’) or processed into a form that will preserve their pharmacological efficacy until they reach their therapeutic destination. Because the cost of transporting and storing drugs using refrigeration is expensive and requires constant temperature monitoring to insure that the drug has not been exposed to environmental conditions that render unsafe for use as a therapeutic product, technologies such as lyophilization are becoming more prevalent. The packaging and technologies developed and marketed for safe and reliable point-of-care drug reconstitution devices are benefiting from this market trend. This report examines commercial drug reconstitution devices and systems and their impact on the injectable drug delivery sector.

Bar_GraphGreystone Drug Reconstitution Systems Report Prospectus (Download PDF)

Blue document Point-of-Care Drug Reconstitution Systems to 2020 Report Order Form (PDF)


Point-of-Care Drug Reconstitution Devices – Highlights

· Analyzes therapeutic demand drivers and evaluates the market impact and potential of commercial drug reconstitution systems

· Provides analysis of injectable drugs for reconstitution and assesses key market segments, market dynamics and market demographics

· Forecasts Injectable drug product demand by indication and therapy to 2020

· Profiles reconstitution system suppliers, their product activities, business strategies, and corporate alliances and affiliations

Point-of-Care Drug Reconstitution Devices – Summary of Contents

Executive Summary
Market Dynamics
Prolonging the Shelf Life of Biological Drugs
Distribution Strategies
Formulation Strategies
Lyophilization and Reconstitution at the Point of Use
Healthcare Economics and Reconstitution Systems
What’s Driving the Growth in Engineered Reconstitution Systems?
Biological Drugs Proliferating
The Trend toward Self-Administration
Shifting Demographics
Innovation in Disposable Device Designs
Therapeutic Demand Drivers
Competitive Landscape
Risk Factors
Drug Reconstitution Systems – Commercial Devices
Vial Adapters
Vial-to-Vial Systems
Needle-less Transfer Devices
Direct Connect to Vial
Direct Connect to Cartridge
Dual Chamber Syringes
Dual Chamber Cartridges
Closed Drug Transfer
Reconstitution System Design Factors
Stability and Material Selection Issues
Disposable Drug Cartridges
Single vs Multi-Dose Devices
Human Engineering/Ergonomics
Drug Reconstitution – Therapeutic Sector Analysis
Antibiotics/Antivirals
Antibodies
Autoimmune Diseases
Arthritis
Crohn’s Disease
Lupus
Multiple Sclerosis
Psoriasis
Blood Proteins
Hepatitis
Hemostats
Hormone Replacement
Human Growth Hormone
Oncology
Osteoporosis
Reproductive Medicine
Vaccines
Market Factors
Syringe Disposal
Regulatory Issues
Patient Compliance
Healthcare Economics
Company ProfilesDrug Reconstitution Systems – Company Profiles